4-(Piperazin-1-yl)benzene-1-sulfonamide → (S)-(-)-3-Bromo-4-[4-[2-(6-bromoisochroman-1-yl)ethyl]piperazin-1-yl]benzenesulfonamide

참여 물질

역할	이름	HCID	투입량
반응물	4-(Piperazin-1-yl)benzene-1-sulfonamide	HCID 901897	—
반응물	2-(6-Bromoisochroman-1-yl)ethanol	HCID 23288830	—
반응물	3-Bromo-4-(piperazin-1-yl)-benzenesulfonamide hydrochloride	HCID 23288838	—
반응물	1-(2-Bromo-4-methoxyphenyl)piperazine	HCID 23288928	—
생성물	(S)-(-)-3-Bromo-4-[4-[2-(6-bromoisochroman-1-yl)ethyl]piperazin-1-yl]benzenesulfonamide	HCID 54523419	—

반응 단계

Following the general procedure of EXAMPLE 49 and making non-critical variations, 2-(6-bromoisochroman-1-yl)ethanol (LXXIX, 0.399 g) and 3-bromo-4-(piperazin-1-yl)- benzenesulfonamide hydrochloride (VIII, Chart C, 0.544 g; prepared by the method of EXAMPLE 37 but using 4-(piperazin-1-yl)benzenesulfonamide (IV) in place of 1-(4-methoxyphenyl)piperazine) are combined to give the title compound; mp 206-208°; MS (m/z) 557 and 559; IR (mineral oil) 1165, 1338, 1450, 616, 1586 and 731 cm-1.

출처 및 근거

DOI	10.6084/m9.figshare.5104873.v1
특허 번호	US06133446
출처 데이터셋	uspto-grants-2000_10
ORD ID	ord-73d7d63e4ffc4b4b81b5d8590bff1598
출처 메모	uspto-grants-2000_10